DDInter624 DDInter1771
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Nevirapine
Nevirapine {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Ethotoin
Ethotoin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Phenobarbital
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Colchicine
Colchicine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Nevirapine (Compound) and Nevirapine may lead to a major life threatening interaction when taken with Teriflunomide
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ethotoin (Compound) and Ethotoin may lead to a major life threatening interaction when taken with Teriflunomide
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine may lead to a major life threatening interaction when taken with Teriflunomide
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Teriflunomide
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may lead to a major life threatening interaction when taken with Teriflunomide
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Colchicine (Compound) and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide